IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kistner, et al.

Application No.: 10/006,671

Filed: December 10, 2001

For: ENVELOPED VIRUS VACCINE AND METHOD OF PRODUCTION

Customer No.: 20350

Declaration of Kistner and Reiter

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

We, Otfried Kistner and Manfred Reiter, being duly warned that willful false statements and the like are punishable by fine or imprisonment or both, under 18 U.S.C. § 1001, and may jeopardize the validity of the patent application or any patent issuing thereon, state and declare as follows:

1. All statements herein made of our own knowledge are true and statements made on information or beliefs are believed to be true.

2. I, Otfried Kistner, am currently a Scientist at Baxter BioScience, in Orth/Donau, Austria. I have worked in the field of Virology and Vaccine development for 22 years. I have a Ph.D. degree in virology from the Justus –Liebig University of Giessen. A copy of my *Curriculum Vitae* is attached as Exhibit A. I, Manfred Reiter, am currently a Scientist and Director of Upstream Process Development at Baxter BioScience, in Orth/Donau, Austria. I have worked in the field of process development for 20 years. I have a Ph.D. degree in Biotechnology from the University of Agriculture and Forestry, Vienna . A

copy of my *Curriculum Vitae* is attached as Exhibit B. We are the joint inventors of the above-referenced application, filed on December 10, 2001.

3. We have reviewed the Office Action mailed on October 12, 2005 in connection with the above-referenced application. We understand that the Examiner has rejected claims 1, 2, 4, 7-9, 11, 14-17 and 27-31 as being allegedly obvious over U.S. Patent No. 5,789,245, Dubensky *et al.* (herein "Dubensky"). In particular, we understand that the Examiner asserts that "[H]ad one of ordinary skill performed Dubensky's method with RRV, the virus intermediate would have necessarily been about 97% pure," as achieved in our methods. This declaration is provided to show that, in fact, Dubensky's method cannot produce virus of the purity achieved by our method.

4. We have performed an experiment in the laboratory wherein we carried out Dubensky's method next to our own method in order to obtain RRV intermediate so that we could test and compare its purity. A VERO cell culture was infected with RRV, incubated and propagated in a bioreactor. More specifically, cells of a working cell bank were expanded in T-flasks and roller bottles with a split ratio of 1:6. Propagation of the cells was performed in a stirred tank bioreactor using CYTODEX3 microcarrier as attachment substrate. The cells were grown at 37°C. The culture conditions of oxygen saturation 20% +/- 10% and pH 7.25 +/- 0.35 were kept constant during virus propagation. A serum free VERO cell culture was infected with RRV at a multiplicity of infection of 0.001. After an incubation time of three days (66 hrs) at 37°C the virus was harvested from the bioreactor.

5. First, we followed Dubensky's teachings and passed the harvested virus through a 0.8/0.65 micron filter in order to clarify the crude RRV according to Dubensky's method (see column 120 in U.S. Patent No. 5,789,245). Second, we followed the teachings of the specification and passed the virus harvest (from the same bioreactor), after separation at ~9000g through a 1.2 micron filter and then through a 0.45 micron filter and finally through a 0.22 micron filter in order to clarify the crude RRV according to our own

method (see page 12, paragraph 049 of the specification). We then assessed the purity of each virus intermediate through Vero-DNA, protein and TCID50 analysis

6. The results showed that the RRV intermediate obtained with our method has a DNA content of 11.8 ng (0.45μ filter) and 11.9 ng (0.22m filter) per 10^7 TCID50 while the RRV intermediate obtained with Dubensky's method has a DNA content of 95.7 ng DNA per 10^7 TCID50. In addition, we have compared the purity of the virus intermediates (obtained with each method) on a DNA to total protein basis and established that Dubensky's method would only lead to an intermediate virus product of 1.62ng DNA per μg protein. In comparison, our method leads to substantially higher purity of the intermediate with a DNA content of 0.23 ng per μg of protein (1.2/45μ filtration) and a DNA content of 0.08 ng per μg protein for the 1.2/0.45μ/0.22μ filtration. Both size exclusions, 0,2 and 0.45 were chosen according to the published pore size range of 0.1-0.5 micron. In addition, we have filtered the 0.8/0.65 micron filtrate (intermediate according to Dubensky's method) with a 0.22micron filter. With this additional filtration step according to our method a significant decrease in DNA content to 63.4 ng/10^7 TCID50and an improved DNA/protein ratio 0.73ng per μg of protein could be achieved. For all experiments identical starting material with a TCID50 of 4.91 x 10^7 was used. The results are summarized in the tables below:

THE CLAIMED METHOD		
	DNA/Virus Titer [ngDNA/10^7($TCID_{50}$/ml)]	DNA/Protein [ngDNA/μgProtein]
Filtration: 1.2 μm/0.45 μm	11.8	0.23
Filtration: 1.2 μm/0.45/0.2 μm	11.9	0.08

DUBENSKY'S METHOD		
	DNA/Virus Titer [ngDNA/10^7($TCID_{50}$/ml)]	DNA/Protein [ngDNA/μgProtein]
Filtration: 0.8 μm/0.65 μm	95.7	1.62
Filtration: 0.8 μm/0.65 μm/0.2μm	63.4	0.73

Date Otfried Kistner, Ph.D.

Date Manfred Reiter, Ph.D.

60746891 v1

Baxter
BioScience

Curriculum Vitae

Name	Manfred Reiter
Degrees	Dipl. Ing., Dr. rer. nat.
Position	Director Upstream Process Development Baxter BioScience
Location	Biomedical Research Center Orth/Donau

Education

1966 – 1970	Primary School
1970 – 1978	High School
1978 – 1986	University Agriculture and Forestry, Vienna, Austria
1986	Diplom Ingenieur (eq. Masters Degree)
1989	PhD

How long at Baxter BioScience 12 years

Job experience

1983 – 1986	Fermentation technology
1986 – 1989	Cell culture technology (Vero, CHO, Hybridoma)
1991 – 1993	Lecturer for animal cell biotechnology at Institute Applied Microbiology
1993	Immuno AG, Biomedical Research Center, Orth, Austria
1998	Manager Microbiological and Cellbiological Process Development
2000	Director Upstream Process Development Baxter BioScience

Fields of expertise Biotechnology, Microbiology, Cell Culture, Screening, Fermentation Technology Recombinants and Vaccines, Separation, Filtration, Ultracentrifugation, Virus Inactivation, GMP Cell Banking, Clinical Manufacturing, Scale-up

M. Reiter 17.03.2006

M. Reiter

PUBLICATIONS / PATENTS / AWARDS

Reiter M (1986) Verwertung und Entsorgung von Kartoffelfruchtwasser der Stärkefabrikation durch Methangärung. Diplomarbeit, Institut für Angewandte Mikrobiologie, Univ. für Bodenkultur, Wien.

Jungbauer A, Tauer C, Wenisch E, Steindl F, Purtscher M, Reiter M, Unterluggauer F, Buchacher A, Uhl K and Katinger HWD(1989) Pilot Scale Production of a Human Monoclonal Antibody against Human Immonodeficiency Virus HIV-1. Journal of Biochemical and Biophysical Methods 19, 223-240.

Wenisch E, Jungbauer A, Tauer C, Reiter M, Gruber G, Steindl F and Katinger HWD (1989) Isolation of Human Monoclonal Antibody Isoproteins using Preparative Isoelectric Focusing in Immobiline pH Gradients. Journal Biochemical and Biophysical Methods 18, 309-322.

Jungbauer A, Tauer C, Reiter M, Purtscher M, Wenisch E, Steindl F, Buchacher A and Katinger HWD (1989) Comparison of Protein-A, Protein-G and Copolymerized Hydroxylapatite for the Purification of Human Monoclonal Antibodies. Journal of Chromatography 476, 257-268.

Weigang F, Reiter M, Jungbauer A and Katinger HWD (1989) Analysis of Carbohydrates and Organic Acids in Presence of Ortho- Phosphate using Refractive Index and UV Detection. Journal of Chromatography 497, 59-68.

Reiter M (1989) Realisierung einer industriellen Produktionstechnologie mit matrix-adhärenten Säugetierzellen am Beispiel *Vero*. Dissertation, Institut für Angewandte Mikrobiologie, Universität für Bodenkultur, Wien.

Hohenwarter O, Reiter M, Blüml G, Gaida T, Schmatz C, Zach N und Hermann Katinger (1990) Einsatz poröser Microcarrier in der tierischen Zellkultur. In: Synopsis 1989, S. 133-139, Eigenverlag Institut für Angewandte Mikrobiologie.

Weigang F, Kral G, Kuhn T, Reiter M, Ernst W und Katinger H (1990) Reversed-Phase High-Performance Liquid Chromatography von Opaderivaten der Aminosäuren zur Fermentationskontrolle tierischer Zellen. In: Synopsis 1989, S. 133-139, Eigenverlag Institut für Angewandte Mikrobiologie.

Weigang F, Kral G, Reiter M, Kuhn T und Katinger H (1990) High-Performance Liquid Chromatography Analyse von Kohlehydraten und organischen Säuren zur Fermentationskontrolle in der Zellkultur. In: Synopsis 1989, S. 128-132, Eigenverlag Institut für Angewandte Mikrobiologie.

Reiter M, Weigang F, Ernst W and Katinger HWD (1990) High Density Microcarrier Culture with a new Device which allows Oxygenation and Perfusion of Microcarrier Cultures. Cytotechnology 3, 39-42.

Jungbauer A, Steindl F, Grunow R, Porstman T, Reiter M, Ernst W, Purtscher M, Tauer C, Wenisch E und Katinger HWD (1990) Pilotproduktion von Humanen Monoklonalen Antikörpern gegen HIV-1. Zeitschrift für Klinische Medizin 45, 351-354.

Reiter M, Hohenwarter O, Gaida T, Zach N, Schmatz C, Blüml G,Weigang F, Nilsson K and Katinger H (1990) The use of Macroporous Gelatin Carriers for the Cultivation of Mammalian Cells in Fluidised Bed Reactors. Cytotechnology 3, 271-277.

Borth N, Steindl F, Weigang F, Reiter M and Katinger H (1990) A Continuous Multistage Roller Reactor for Animal Cell Culture: 1. Patterns of Growth, Production and Catabolism of a Murine Hybridoma. Cytotechnology 3, 253-258.

Wenisch E, Wimmer K, Harant H, Schmatz C, Reiter M, Gaida T, Blüml G, Hohenwarter O, Katinger H und Righetti PG (1991) Two-Dimensional Gel Electrophoresis for Controlling Culture Supernatants of Mammalian Cell Culture Large-Scale Production Systems. In: Proceedings of the International Meeting on Two-Dimensional Electrophoresis, London, Uk, July 16-18, 1991, p. 263-267 (Dunn MJ, ed.), Zebra Printing, UK.

Reiter M, Blüml G, Gaida T, Zach N, Doblhoff-Dier O, Unterluggauer F, Noe M, Plail R, Huss S and Katinger H (1991) Modular Fluidized Bed Bioreactor Technology. Bio/Technology 9, 1100-1102.

Doblhoff-Dier O, Huss S, Plail R, Litos R, Unterluggauer F, Reiter M and Katinger H (1991) A Modular Computer Controlled Fermentation Pilot Plant. Process Biochemistry 26, 201-207.

Doblhoff-Dier O, Plail R und Reiter M (1991) Laborsicherheit. In: "Studie Gen- und Biotechnologie", S.119-189, Österreichisches Umweltbundesamt, Eigenverlag.

Wimmer K, Harant H, Wenisch E, Schmatz C, Reiter M, Hohenwarter O und Katinger H (1991) Charakterisierung von Änderungen der Genexpression einer rekombinanten CHO-Zellinie in serumhaltigem und proteinfreiem Kulturmedium mit Hilfe der hochauflösenden 2-D Elektrophorese. In: Elektrophorese Forum (Hrsg. Radola BJ), S. 407-411, Eigenverlag TU München, BRD.

Reiter M, Zach N, Gaida T, Blüml G, Doblhoff-Dier O, Unterluggauer F, Katinger H (1992) Oxygenation in Fluidized Bed Bioreactors using the Microsparging Technique. In: Animal Cell Technology: Development Processes and Products (Spier and Griffiths and MacDonald, eds.) pp. 386-390, Butterworth-Heinemann Ltd., Oxford, UK.

Blüml G, Reiter M, Zach N, Gaida T, Schmatz C, Strutzenberger K, Mohr T and Katinger H (1992). Development of a new type of macroporous carrier. In: Animal Cell Technology: Development Processes and Products (Spier and Griffiths and MacDonald, eds.) pp. 501-504, Butterworth-Heinemann Ltd., Oxford, UK.

Unterluggauer F, Doblhoff-Dier O, Reiter M, Blüml G, Zach N, Gaida T, Kral G, Schmatz C and Katinger H (1992) Scale-up of a fluidized bed reactor operated with porous glass carriers. In: Animal Cell Technology: Development Processes and Products (Spier and Griffiths and MacDonald, eds.) pp. 505-507, Butterworth-Heinemann Ltd., Oxford, UK.

Reiter M, Blüml G, Gaida T, Zach N, Schmatz C, Borth N, Hohenwarter O and Katinger H (1992) High density aggregate culture of recombinant CHO cells in fluidized bed bioreactors. In: Animal Cell Technology: Development Processes and Products (Spier and Griffiths and MacDonald, eds.) pp. 421-423, Butterworth-Heinemann Ltd., Oxford, UK.

M. Reiter 17.03.2006

Borth N, Schmatz C, Hofbaur J, Reiter M, Gaida T, Blüml G and Katinger H (1992) Adaptation of r-CHO cells to growth in serumfree medium: A flow cytometric study. In: Animal Cell Technology: Development Processes and Products (Spier and Griffiths and MacDonald, eds.) pp. 140-144, Butterworth-Heinemann Ltd., Oxford, UK.

Borth N, Reiter M, Blüml G, Schmatz C, Gaida T and Katinger H (1992) Determination of division rates of rCHO cells in high density and immobilized fermentation systems by flow cytometry. Cytotechnology 8, 207-214.

Harant H, Wimmer K, Wenisch E, Strutzenberger K, Reiter M, Blüml G, Gaida T, Schmatz C and Katinger H (1992). Two-dimensional electrophoresis as a tool for control of quality consistency in production systems using animal cells. Cytotechnology 8, 119-127.

Reiter M, Blüml G, Zach N, Gaida T, Kral G, Assadian A, Schmatz C, Strutzenberger K, Hinger S and Katinger H (1992) Monoclonal Antibody Production using the Porous Glass Bead Immobilization Technique. Annals of the New York Academy of Sciences 665, 146-151.

Reiter M, Borth N, Blüml G, Wimmer K, Harant H, Zach N, Gaida T, Schmatz C and Katinger H (1992) Flow cytometry and 2-dimensional electrophoresis (2-DE) for system evaluation of long term continuous perfused animal cell cultures in macroporous beads. Cytotechnology 9, 247-253.

Katinger H, Assadian A, Blüml G, Borth, Buchacher A, Doblhoff-Dier O, Gaida T, Reiter M, Schmatz C, Strutzenberger K, Steinfellner W, Unterluggauer F and Zach N (1993) Long term stability of continuously perfused animal cells immobilized on novel macroporous microcarriers. Proceedings K Mosbach Meeting, Lund Sweden.

Blüml G, Reiter M, Zach N, Gaida T, Schmatz C, Assadian A, Strutzenberger K and Katinger H (1994) Protein-free culture of r-CHO and hybridoma cells on the macroporous Polypore carrier. Animal Cell Technology: products of today, prospects for tomorrow (Spier and Griffiths and Berthold, eds.) pp. 267-269, Butterworth-Heinemann Ltd., Oxford, UK.

Gaida T, Schich W, Reiter M, Blüml G, Zach N and Katinger H (1994) A simple magnetic driven mini-reactor for fluidized and packed beds. Animal Cell Technology: products of today, prospects for tomorrow (Spier and Griffiths and Berthold, eds.) pp. 290-292, Butterworth-Heinemann Ltd., Oxford, UK.

Reiter M, Buchacher A, Blüml G, Zach N, Steinfellner W, Schmatz C, Gaida T, Assadian A and Katinger H (1994) Production of the HIV-1 neutralizing human monoclonal antibody 2F5: stirred tank versus fluidized bed culture. Animal Cell Technology: products of today, prospects for tomorrow (Spier and Griffiths and Berthold, eds.) pp. 333-335, Butterworth-Heinemann Ltd., Oxford, UK.

Loibner AP, Zach N, Doblhoff-Dier O, Reiter M, Bayer K and Katinger H (1994) On-line glucose control of animal cell cultures in fluidized beds. Animal Cell Technology: products of today, prospects for tomorrow (Spier and Griffiths and Berthold, eds.) pp. 372-375, Butterworth-Heinemann Ltd., Oxford, UK.

M. Reiter 17.03.2006

Unterluggauer F, Doblhoff-Dier O, Tauer C, Jungbauer A, Gaida T, Huss S, Litos R, Plail R, Reiter M, Schmatz C, Zach N and Katinger H (1994) Stable, Continuous Large-Scale Production of Human Monoclonal HIV-1 Antibody Using a Computer-Controlled Pilot Plant. BioTechniques 16, 140-147.

Reiter M and Blüml G (1994) Large Scale mammalian cell culture. Current Opinion in Biotechnology 5, 175-179.

Fischer B E, Schlokat U, Mitterer A, Reiter M, Mundt W, Turecek P L, Schwarz H P and Dorner F (1995) Structural analysis of recombinant von Willebrand factor produced at industrial scale fermentation of transformed CHO cells co-expressing recombinant furin. FEBS Letters 375, 259-262.

Katinger H, Assadian A, Blüml G, Borth N, Buchacher A, Doblhoff O, Gaida T, Reiter M, Schmatz C, Strutzenberger K, Steinfellner W, Unterluggauer F, Zach N (1996) Long-term stability of continuously perfused animal cells immobilized on novel macroporous microcarriers. Advances in Molecular and Cell Biology 15a, Biochemical Technology (Bittar, Danielsson and Bülow, eds.) pp. 193-207, JAI Press Inc., Greenwich, Connecticut, USA.

Fischer B E, Schlokat U, Mitterer A, Grillberger L, Reiter M, Mundt W, Dorner F and Eibl J (1996) Differentiation between proteolytic and autocatalytic conversion of human prothrombin. Activation of recombinant human prothrombin and recombinant D419N-prothrombin by snake venoms from *Echis carinatus* and *Oxyuranus scutellatus*. Protein Engineering 9, 921-926.

Fischer B E, Schlokat U, Mitterer A, Savidis-Dacho H, Grillberger L, Reiter M, Mundt W, Dorner F and Eibl J (1996) Rational design, recmbinant preparation and *in vitro* and *in vivo* characterization of human prothrombin-derived hirudin antagonists. The Journal of Biological Chemistry, 271, 23737-23742.

Fischer B E, Mitterer A, Grillberger L, Reiter M, Mundt W, Dorner F and Eibl J (1996) Effect of Multimerization of human and recombinant von Willebrand Factor on platelet aggregation, binding to collagen and binding of coagulation Factor VIII. Thrombosis Research 84, 55-66.

Fischer B E, Kramer G, Mitterer A, Schlokat U, Grillberger L, Reiter M, Mundt W, Dorner F and Eibl J (1996) Immobilized Hirudin and Hirudin-Based Peptides used for the Purifikation of recombinant human Thrombin prepared from Recombinant Human Prothrombin. Protein Expression and Purification 8, 167-174.

Schlokat U, Fischer B, Mitterer A, Falkner FG, Reiter M, Grillberger L, Mundt W, Preininger A, Mohr G, Siekmann J, Turecek P, Schwarz HP und Dorner F (1997) Herstellung und Charakterisierung von rekombinantem von Willebrand-Faktor zur therapeutischen Anwendung. 26. Hämophilie-Symposion Hamburg 1995 (Scharrer und Schramm, Hrsg.), S. 147-158, Springer-Verlag Berlin Heidelberg.

Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F (1998) Development of a Mammalian Cell (Vero) derived Influenza whole virus vaccine. Vaccine 16, 960-968.

M. Reiter 17.03.2006

Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Eder G and Dorner F (1999) A novel mammalian cell (Vero) derived influenza virus vaccine: Development, characterization and industrial scale production. Wiener Klinische Wochenschrift 111/5:207-214.

Besman MJ, Dorner F, Jhingan A, Kaliwoda M, Kashi RS, Kumar HP, Mitterer A, Mundt W, Reiter M, Woehrer W (2000) Development of a new recombinant anti-haemophilic factor (rAHF) and comparative characterization with recombinate using biochemical biophysical techniques. Haemophilia 6:357-358.

M. Reiter 17.03.2006

PATENTS

Katinger H, Reiter M, Blüml G, Gaida T und Zach N (1991) Reaktor zur Durchführung biologischer Reaktionen mittels Biokatalysatoren. Österreichisches Patent AT 9193.

Katinger H, Reiter M, Blüml G, Gaida T und Zach N (1991) Reactor for performing biological reactions using biocatalysts. EP 495769.

Katinger H, Reiter M, Blüml G, Gaida T und Zach N (1991) Reactor for carrying out biological reactions by means of biocatalysts. US-Patent 5246855.

Katinger H, Blüml G, Zach N, Reiter M, Gaida T und Rauschert B (1992) Thermisch sterilisierbarer poröser Trägerkörper für Biokatalysatoren. Österreichische Patentanmeldung AT 92/00081.

Katinger H, Blüml G, Zach N, Reiter M, Gaida T und Rauschert B (1993) Heat-sterilizable porous carrier for biocatalysts. US-Patent 07/980806.

Fischer B, Mitterer A, Dorner F, Schwarz HP, Turecek P, Eibl J, Falkner F, Schlokat U, Mundt W, Reiter M, Den-Bouwmeester R (1996) Verfahren zur Gewinnung von hochreinem von Willebrand Faktor. PCT EP95 03892.

Reiter M, Mundt W and Dorner F (2000). Recombinant cell clone having increased stability in serum- and protein-free medium and a method of recovering the stable cell clone and the production of recombinant proteins by using a stable cell clone. US 6,100,061.

Reiter M and Mundt W (2005) Method for large scale production of virus. US 6,951,752.

Meyer H, Reiter M, Mundt W, Barrett N and Dorner F (2005) Method for large scale production of Hepatitis A virus. US 6,855,535.

Mitterer A, Tauer C, Reiter M and Mundt W (2004) Method for isolation and purification of trypsin from pronase protease an use thereof. US 6,830,917.

Reiter M, Mundt W, Dorner F, Grillberger L and Mitterer A (2003) Medium for the protein-free and serum-free cultivation of cells. Patent application US 2003/0203448A1.

Reiter M, Mundt W, Grillberger L and Kraus B (2004) Animal protein free media for cultivation of cells. Patent application US 2004/0077086A1.

Kistner O, Reiter M, Bruehmann A, Barrett N, Mundt W and Dorner F (2003) Enveloped virus vaccine and method for production. Patent application US 2003/0108859A1.

M. Reiter 17.03.2006

Baxter Technical Awards

Science and Technology Award 1997, Baxter International Inc.
The next Generation of Recombinate™

Outstanding Science and Technology Award 1998, Baxter International Inc.
Vero Cell Derived Vaccines

Special Accomplishment Award 1999, Baxter International Inc.
Novel Vero Cell Derived Influenza Vaccine

Special Accomplishment Award 1999, Baxter International Inc.
Development of a Ross River Candidate Vaccine

Special Accomplishment Award 1999, Baxter International Inc.
Preclinical Development of a Hepatitis A Virus Vaccine

Outstanding Science and Technology Award 1999, Baxter International Inc.
Protein-free Culture Medium for Therapeutics and Vaccines

Special Accomplishment Award 2000, Baxter International Inc.
Guaranteed TSE-free Trypsin for Biotechnological Processes

Customer First Award 2001, Baxter International Inc.
Development and Delivery of a Candidate Smallpox Vaccine

Distinguished Scientist Award 2002, Baxter International Inc.
Production of 500 Million Dose Equivalent of Smallpox Vaccine

M. Reiter 17.03.2006

Curriculum Vitae

Name:	Otfried Kistner
Degrees:	Ph.D.
Position:	Senior Director Virology
Location:	Baxter BioScience, Biomedical Research Center, Orth/Donau, Austria

Education:

1978-1984	Justus-Liebig-University, Giessen, Germany Diploma in Biology
1984-1987	Justus-Liebig-University, Giessen, Germany Ph.D. in Virology

Other training:	Cell Biology, Immunology, Biochemistry, Statistics

Employment History:

1982 - 1984	Trainee, Institute of Virology, University of Giessen, Germany
1984 - 1987	Research Fellow, Institute of Virology, University of Giessen, Germany
1987 - 1988	Research Assistant, Institute of Virology, University of Giessen, Germany
1988 - 1990	Research Scientist Virology, Immuno AG, Austria
1991 - 1996	Head of Laboratory Virology, Immuno AG, Austria
1997 - 1998	Head of Department Experimental Virology, Baxter Hyland Immuno, Austria
1998 - 1999	Head of Departments Experimental Virology and Viral Vaccines, Baxter Hyland Immuno, Austria
2000 - 2004	Director Virology (responsible for departments "Experimental Virology", "Viral Vaccines" and "Preclinical Research"), Baxter BioScience, Austria
since 2004	Senior Director Virology / Viral Vaccines, Baxter BioScience, Austria

Fields of Expertise:	Vaccine Development (R & D , Preclinic, Clinic in part) Establishment of new Methodologies, Quality Control, Regulatory Affairs, Biological Safety
Number of publications:	19 Publications, 9 Patents

Publications:

1. O. Kistner, H. Müller, H. Becht and C. Scholtissek (1985)
Phosphopeptide Fingerprints of Nucleoproteins of Various Influenza A Strains Grown in Different Host Cells.
J. Gen. Virol. **66**, 465-472

2. C. Scholtissek, H. Bürger, O. Kistner and K. F. Shortridge (1985)
The Nucleoprotein as a Possible Major Factor in Determining Host Specifity of Influenza H3N2 Viruses.
Virology **147**, 285-294

3. C. Scholtissek, H. Bürger, O. Kistner and K. F. Shortridge (1987)
The Nucleoprotein (NP) as a Possible Major Factor in Determining Host Specifity of Influenza H3N2 Viruses of Southern China.
In: The Biology of Negative Strand Viruses, Eds.: B. Mahy and D. Kolakofsky 417-423, Elsevier, Amsterdam, Oxford, New York

4. O. Kistner, K. Müller and C. Scholtissek (1989)
Differential Phosphorylation of the Nucleoprotein of Influenza A-Viruses
J. Gen. Virol. **70**, 2421-2431

5. F. G. Falkner, P. Turecek, R. T. A. MacGillivray, W. Bodemer, F. Scheiflinger, S. Kandels, A. Mitterer, O. Kistner, N. Barrett, J. Eibl and F. Dorner (1992)
High Level Expression of Active Human Prothrombin in a Vaccinia Virus Expression System.
Thromb. Haemost. **68**, 119-124

6. N. Barrett, O. Kistner and F. Dorner (1993)
Antigens and Immunogens: Viruses. In: Methods of Immunological Analysis,Vol. 2: Sampley and Reagents, Eds.: R. F. Massayeff, W. H. Albert and N. A. Staines. Publishers VCH, Weinheim. 116-132

7. U. Schlokat, B. Fischer, S. Herlitschka, G.. Antoine, A. Preininger, G. Mohr, M. Himmelspach, O. Kistner, F. G. Falkner and F. Dorner (1996)
Production of Highly Homogeneous and Structurally Intact Recombinant von Willebrand Factor Multimers by Furin-Mediated Propeptide Removal *in vitro*.
Biotechnol. Appl. Biochem. **24**, 257-267

8. M. Gerencer, P. N. Barrett, O. Kistner, A. Mitterer and F. Dorner (1998)
Natural IgM Antibodies from Baby Rabbit Serum Bind High-Mannose Glycans on HIV-1 Type 1 Glycoprotein 120/160 and Activate Classic Complement Pathway.
AIDS Res. Hum. Retrov. **14**, 599-605

9. O. Kistner, P. N. Barrett, W. Mundt, M. Reiter, S. Schober-Bendixen and F. Dorner (1998)
Development of a Mammalian Cell (VERO)-Derived Candidate Influenza Virus Vaccine.
Vaccine **16**, 960-968

10. O. Kistner, P. N. Barrett, W. Mundt, M. Reiter, S. Schober-Bendixen, G. Eder and F. Dorner (1999)
Development of a Vero Cell-Derived Influenza Whole Virus Vaccine.
Dev. Biol. Stand. **98**, 101-110

11. O. Kistner, P. N. Barrett, W. Mundt, M. Reiter, S. Schober-Bendixen, G. Eder and F. Dorner (1999)
A Novel Mammalian Cell (Vero) Derived Influenza Virus Vaccine: Development, Characterization and Industrial Scale Production
Wien. klin. Wochenschr. **111/5**, 207-214

12. P. Brühl, A. Kerschbaum, O. Kistner, N. Barrett, F. Dorner and M. Gerencer (2001)
Humoral and Cell-Mediated Immunity to Vero Cell-Derived Influenza Vaccine.
Vaccine **19**, 1149-1158

13. O. Kistner, P. N. Barrett, W. Mundt, M. Reiter, S. Schober-Bendixen, G. Eder and F. Dorner (2001)
Entwicklung eines neuen, aus permanenten Zellen gewonnenen Grippe-Impfstoffs
Altex **18**, 50-54

14. I. Jabbal-Gil, W. Lin, O. Kistner, S. S. Davis, and L. Illum (2001)
Polymeric Lamellar Substrate Particles for Intranasal Vaccination
Advanced Drug Delivery Reviews **51**, 97-111

15. U. Hainz, K. Aigner, E. Asch, P. Berger, F. Böhmer, B. Feldkircher, B. Horvath, B. Jenewein, H. Kassal, O. Kistner, H. Mack, K.-P. Pfeiffer, K. Pils, J. Plank, D. Renner, M. Sauerwein-Teissl, E. Schwanzer, K. Trieb, and B. Grubeck-Loebenstein (2002)
Impfschutz im Alter: Sind österreichische Senioren durch Impfungen ausreichend geschützt?
Wien. klin. Wochenschr. **114**, 187-193

16. T.R. Kreil, A. Berting, O. Kistner, and J. Kindermann (2003)
West Nile Virus and the Safety of Plasma Derivatives: Verification of High Safety Margins, and the Validity of Predictions based on Model Virus Data
Transfusion **43**, 1023-1028

17. A. Berting, W. Goerner, M. Spruth, O. Kistner, and T.R. Kreil (2005)
Effective Poxvirus Removal by Sterile Filtration during Manufacture of Plasma Derivatives
J. Med. Virol. **75**, 603-607

18. J.S. Oxford, C. Manuguerra, O. Kistner, A, Linde, M. Kunze, W. Lange, B. Schweiger, G. Spala, H. Rebelo de Andrade, P.R. Pérez Brenaq, J. Beytout, L. Brydak, D. Caraffa de Stefano, O. Hungnes, J. Kyncl, E. Montomoli, A. Gil de Miguel, R. Vranckx, and A. Osterhaus (2005)
A New European Perspective of influenza Pandemic Planning with a Particular Focus on the Role of Mammalian Cell Culture Vaccines
Vaccine, **23**, 5440-5449

19. M. Spruth, O. Kistner, H. Savidis-Dacho, E. Hitter, B. Crowe, M. Gerencer, P. Bruehl, L. Grillberger, M. Reiter, C. Tauer, W. Mundt, and P. N. Barrett (2006)
A Double-Inactivated Whole Virus Candidate SARS Coronavirus Vaccine Stimulates Neutralising and Protective Antibody Responses
Vaccine, **24**, 652-661

Patents/Patent Applications:

1. Method for producing biologicals in protein-free culture
   Patent-No's:
   PCT 96/15231; EP 0 791 055; EP 1 213 030; CA 2.205.015; JP 3158157

2. Production of orthomyxoviruses in monkey kidney cells using protein-free media
   Patents No:
   US 6.146.873

3. Method for producing influenza virus and vaccine
   Patent No:
   US 5.698.433

4. Method for producing viruses and vaccine in serum-free culture
   Patent No:
   US 5.753.489

5. Method for controlling the infectivity of viruses
   Patent No:
   US 5.756.341

6. Method of inactivating lipid-enveloped viruses
   Patent-No's:
   AT 405 939; EP 0 864 646; US 6,136,321

7. Novel Influenza virus vaccine composition
   Patent-No's:
   PCT 00/15251; AT 408 615; EP 1 113 816; US 6,372,223

8. Inactivated influenza virus vaccine for nasal or oral adminstration
   Patent-No's:
   PCT 00/47222; AT 407 958; EP 1 144 001; AU 770 923; US 6,635,246; US 6,861,244; US 2004/0096464; US 6,861,244

9. Enveloped virus vaccine and method for production
   Patent-No's: US 2003/0108859, WO 03/049765

Orth/Donau, Austria, December 7, 2005